OBJECTIVES: One potential concern of once-daily protease inhibitor administration is low trough concentrations and ultimately the 'forgiveness' or robustness in comparison with the originally licensed twice-daily dose. To give an estimation of 'forgiveness', we determined the length of time plasma drug concentrations were below target in HIV-infected patients receiving saquinavir/ritonavir regimens. METHODS: Seventy-seven pharmacokinetic profiles (saquinavir/ritonavir 1000/100 mg twice daily, n = 34; 1600/100 mg once daily, n = 26; 2000/100 mg once daily, n = 17) from five studies were combined, presented as twice- and once-daily percentiles (P10-P90) and compared. At percentiles where trough concentrations fell below the alleged minimum effective concentration (MEC; 100 ng/mL), the length of time below MEC was determined. RESULTS: Saquinavir concentrations were below MEC at P10 for 0.7 h for twice-daily saquinavir/ritonavir when compared with 8.6 and 6.6 h for 1600/100 and 2000/100 mg once daily, respectively. At P25, 1600/100 mg once daily produced suboptimal concentrations for 5.5 h in contrast to 0.5 h for 2000/100 mg once daily. CONCLUSIONS: Here, we provide substantive data that indicate once-daily saquinavir, in particular 1600/100 mg, is not as robust as the twice-daily regimen based on a population of UK patients; this raises concern over late or missed doses. However, pharmacokinetic data can only ever be a guide to the impact on long-term efficacy.
OBJECTIVES: One potential concern of once-daily protease inhibitor administration is low trough concentrations and ultimately the 'forgiveness' or robustness in comparison with the originally licensed twice-daily dose. To give an estimation of 'forgiveness', we determined the length of time plasma drug concentrations were below target in HIV-infectedpatients receiving saquinavir/ritonavir regimens. METHODS: Seventy-seven pharmacokinetic profiles (saquinavir/ritonavir 1000/100 mg twice daily, n = 34; 1600/100 mg once daily, n = 26; 2000/100 mg once daily, n = 17) from five studies were combined, presented as twice- and once-daily percentiles (P10-P90) and compared. At percentiles where trough concentrations fell below the alleged minimum effective concentration (MEC; 100 ng/mL), the length of time below MEC was determined. RESULTS:Saquinavir concentrations were below MEC at P10 for 0.7 h for twice-daily saquinavir/ritonavir when compared with 8.6 and 6.6 h for 1600/100 and 2000/100 mg once daily, respectively. At P25, 1600/100 mg once daily produced suboptimal concentrations for 5.5 h in contrast to 0.5 h for 2000/100 mg once daily. CONCLUSIONS: Here, we provide substantive data that indicate once-daily saquinavir, in particular 1600/100 mg, is not as robust as the twice-daily regimen based on a population of UK patients; this raises concern over late or missed doses. However, pharmacokinetic data can only ever be a guide to the impact on long-term efficacy.
Authors: Luisa Valer; Carmen De Mendoza; Daniel González De Requena; Pablo Labarga; Adolfo García-Henarejos; Pablo Barreiro; Francisca Guerrero; Antonio Vergara; Vincent Soriano Journal: AIDS Date: 2002-09-27 Impact factor: 4.177
Authors: Laura Dickinson; Lesley Robinson; John Tjia; Saye Khoo; David Back Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2005-10-13 Impact factor: 3.205
Authors: Laetitia Comté; Bernard Vrijens; Eric Tousset; Paul Gérard; John Urquhart Journal: J Pharmacokinet Pharmacodyn Date: 2007-05-12 Impact factor: 2.745
Authors: Jonathan Shuter; Julie A Sarlo; Tina J Kanmaz; Richard A Rode; Barry S Zingman Journal: J Acquir Immune Defic Syndr Date: 2007-05-01 Impact factor: 3.731
Authors: D L Paterson; S Swindells; J Mohr; M Brester; E N Vergis; C Squier; M M Wagener; N Singh Journal: Ann Intern Med Date: 2000-07-04 Impact factor: 25.391
Authors: Peter G Cardiello; Rolf P van Heeswijk; Elly A Hassink; Preeyaporn Srasuebkul; Apicha Mahanontharit; Tarika M Samor; Wassana Worarien; Jos H Beijnen; Richard M Hoetelmans; Kiat Ruxrungtham; David A Cooper; Joep M Lange; Praphan Phanuphak Journal: J Acquir Immune Defic Syndr Date: 2002-04-15 Impact factor: 3.731
Authors: Margaret A Johnson; Joseph C Gathe; Daniel Podzamczer; Jean-Michel Molina; Christian T Naylor; Yi-Lin Chiu; Martin S King; Thomas J Podsadecki; George J Hanna; Scott C Brun Journal: J Acquir Immune Defic Syndr Date: 2006-10-01 Impact factor: 3.731
Authors: Julio S G Montaner; Malte Schutz; Robert Schwartz; Dushyantha T Jayaweera; Alfred F Burnside; Sharon Walmsley; Michael S Saag Journal: MedGenMed Date: 2006-05-10
Authors: Michael A Collier; Matthew D Gallovic; Eric M Bachelder; Craig D Sykes; Angela Kashuba; Kristy M Ainslie Journal: Pharm Res Date: 2016-05-06 Impact factor: 4.200
Authors: Laura Dickinson; Marta Boffito; David J Back; Saye H Khoo; Anton L Pozniak; Peter Mugyenyi; Concepta Merry; Reshma Saskia Autar; David M Burger; Leon J Aarons Journal: J Antimicrob Chemother Date: 2008-09-29 Impact factor: 5.790
Authors: P Costa; F Bozzano; D Fenoglio; A Beltrame; G Cenderello; A Di Biagio; G Ferrea; G Pagano; A De Maria Journal: Clin Exp Immunol Date: 2009-10 Impact factor: 4.330